Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
Yuzhen Yin(Shanghai Medical College of Fudan University), Qing Xu(Shanghai Medical College of Fudan University)
Cited by 3
Related Papers
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
|Signal Transduction and Targeted Therapy|2019|699
STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
|Frontiers in Oncology|2019|57